1. Home
  2. CUE vs ACOG Comparison

CUE vs ACOG Comparison

Compare CUE & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$4.59

Market Cap

177.0M

Sector

Health Care

ML Signal

N/A

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

N/A

Current Price

$8.90

Market Cap

180.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CUE
ACOG
Founded
2014
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.0M
180.5M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
CUE
ACOG
Price
$4.59
$8.90
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
★ $68.67
$18.20
AVG Volume (30 Days)
★ 552.6K
99.8K
Earning Date
11-16-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.11
41.58
EPS
N/A
★ N/A
Revenue
★ $27,466,000.00
$10,220,275.00
Revenue This Year
N/A
$162.31
Revenue Next Year
N/A
$86.08
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 195.75
N/A
52 Week Low
$0.17
$4.50
52 Week High
$45.50
$10.14

Technical Indicators

Market Signals
Indicator
CUE
ACOG
Relative Strength Index (RSI) 24.71 52.26
Support Level $0.22 $7.69
Resistance Level $33.95 $9.30
Average True Range (ATR) 2.75 0.55
MACD -1.47 0.01
Stochastic Oscillator 8.18 65.54

Price Performance

Historical Comparison
CUE
ACOG

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: